GlycoMimetics (CBIO) Competitors $14.62 +1.35 (+10.17%) As of 06/18/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendSustainabilityTrendsBuy This Stock CBIO vs. OPK, GERN, RGLS, ZBIO, MYGN, RIGL, EBS, VSTM, XOMA, and VNDAShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), Verastem (VSTM), XOMA (XOMA), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. GlycoMimetics vs. Its Competitors OPKO Health Geron Regulus Therapeutics Zenas Biopharma Myriad Genetics Rigel Pharmaceuticals Emergent BioSolutions Verastem XOMA Vanda Pharmaceuticals OPKO Health (NASDAQ:OPK) and GlycoMimetics (NASDAQ:CBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do institutionals and insiders believe in OPK or CBIO? 64.6% of OPKO Health shares are held by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are held by institutional investors. 49.7% of OPKO Health shares are held by company insiders. Comparatively, 4.0% of GlycoMimetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor OPK or CBIO? OPKO Health received 204 more outperform votes than GlycoMimetics when rated by MarketBeat users. However, 68.36% of users gave GlycoMimetics an outperform vote while only 65.60% of users gave OPKO Health an outperform vote. CompanyUnderperformOutperformOPKO HealthOutperform Votes51365.60% Underperform Votes26934.40% GlycoMimeticsOutperform Votes30968.36% Underperform Votes14331.64% Do analysts rate OPK or CBIO? OPKO Health presently has a consensus price target of $2.75, suggesting a potential upside of 113.18%. GlycoMimetics has a consensus price target of $22.00, suggesting a potential upside of 50.48%. Given OPKO Health's higher possible upside, analysts clearly believe OPKO Health is more favorable than GlycoMimetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OPKO Health 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75GlycoMimetics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to OPK or CBIO? In the previous week, GlycoMimetics had 10 more articles in the media than OPKO Health. MarketBeat recorded 10 mentions for GlycoMimetics and 0 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.34 beat GlycoMimetics' score of -0.10 indicating that OPKO Health is being referred to more favorably in the media. Company Overall Sentiment OPKO Health Neutral GlycoMimetics Neutral Which has more volatility & risk, OPK or CBIO? OPKO Health has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Is OPK or CBIO more profitable? GlycoMimetics has a net margin of 0.00% compared to OPKO Health's net margin of -5.66%. OPKO Health's return on equity of -2.85% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets OPKO Health-5.66% -2.85% -1.82% GlycoMimetics N/A -293.92%-206.20% Which has higher earnings & valuation, OPK or CBIO? GlycoMimetics has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOPKO Health$713.10M1.43-$53.22M-$0.07-18.43GlycoMimetics$10K950.30-$37.88M-$46.00-0.32 SummaryOPKO Health and GlycoMimetics tied by winning 9 of the 18 factors compared between the two stocks. Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBIO vs. The Competition Export to ExcelMetricGlycoMimeticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.56M$2.41B$5.21B$8.60BDividend YieldN/A1.54%5.34%4.21%P/E Ratio-0.328.5025.3019.19Price / Sales950.30479.80415.17113.15Price / CashN/A147.5135.3655.76Price / Book1.774.787.766.22Net Income-$37.88M$31.14M$3.15B$248.98M7 Day PerformanceN/A-2.15%-2.14%-1.05%1 Month PerformanceN/A7.22%3.68%2.48%1 Year PerformanceN/A-1.37%36.71%15.36% GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBIOGlycoMimetics2.6836 of 5 stars$14.62+10.2%$22.00+50.5%N/A$8.56M$10K-0.3226Analyst ForecastStock SplitGap DownOPKOPKO Health4.473 of 5 stars$1.38-0.4%$2.75+100.0%+2.4%$1.09B$689.41M-7.244,200Gap UpGERNGeron3.1683 of 5 stars$1.61-0.9%$5.06+215.4%-65.5%$1.02B$116.29M-5.0270Positive NewsRGLSRegulus Therapeutics1.7136 of 5 stars$8.26-0.5%$8.50+3.0%+231.0%$571.53MN/A-7.7130Positive NewsZBIOZenas Biopharma1.5025 of 5 stars$12.20+2.3%$36.67+200.5%N/A$510.38M$15M-3.44N/AMYGNMyriad Genetics4.0407 of 5 stars$5.20+0.1%$14.38+176.9%-78.8%$479.78M$831.30M-4.002,600RIGLRigel Pharmaceuticals3.7192 of 5 stars$22.25+1.8%$36.40+63.6%+114.5%$397.56M$203.08M158.90160Positive NewsEBSEmergent BioSolutions4.438 of 5 stars$6.74+3.9%$14.33+112.6%+4.1%$366.59M$930.30M-1.652,420Positive NewsVSTMVerastem3.2005 of 5 stars$6.25+2.3%$13.63+118.0%+58.7%$342.55M$10M-1.9550XOMAXOMA4.1215 of 5 stars$25.16-0.5%$69.50+176.3%+10.4%$299.85M$13.05M-7.2010News CoverageVNDAVanda Pharmaceuticals4.6724 of 5 stars$4.63+0.8%$16.50+256.7%-28.5%$273.10M$201.35M-14.48290Positive News Related Companies and Tools Related Companies OPKO Health Competitors Geron Competitors Regulus Therapeutics Competitors Zenas Biopharma Competitors Myriad Genetics Competitors Rigel Pharmaceuticals Competitors Emergent BioSolutions Competitors Verastem Competitors XOMA Competitors Vanda Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBIO) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CBIO Stock Free CBIO Stock Alerts